2seventy bio, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of contingent consideration
Depreciation and amortization
Stock-based compensation expense
Goodwill impairment charge
Gain (loss) on sale of assets
Novo
Regeneron
Other non-cash items
Changes in operating assets and liabilities:
Prepaid expenses and other assets
Operating lease right-of-use assets
Accounts payable
Accrued expenses and other liabilities
Operating lease liabilities
Deferred revenue
Collaboration research advancement
Net cash used in operating activities
Cash flows from investing activities:
Purchases of property, plant and equipment
Proceeds from sale of assets
Novo
Regeneron
Proceeds from sale of equipment
Purchases of marketable securities
Proceeds from maturities of marketable securities
Purchase of intangible assets
Purchase of restricted investments
Proceeds from maturities of restricted investments
Net cash provided by investing activities
Cash flows from financing activities:
Transfers from bluebird bio
Proceeds from issuance of common stock in public offering, net of issuance costs
Proceeds from issuance of common stock to Regeneron, net of issuance costs
Proceeds from issuance of common stock in private placement, net of issuance costs
Proceeds from exercise of stock options and ESPP contributions
Net cash provided by financing activities
Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents
Cash, cash equivalents and restricted cash and cash equivalents at beginning of year
Cash, cash equivalents and restricted cash and cash equivalents at end of year
Supplemental cash flow disclosures:
Purchases of property, plant and equipment included in accounts payable and accrued expenses
Right-of-use assets obtained in exchange for operating lease liabilities
Non-cash return of bRT-related assets to bluebird bio
Increase of right-of-use asset and associated lease liability due to lease reassessment
Issuance of unrestricted stock awards to settle accrued employee compensation
Cash paid during the period for interest
Cash paid during the period for income taxes

Reconciliation of cash, cash equivalents and restricted cash and cash equivalents:
Cash and cash equivalents
Restricted cash and cash equivalents included in restricted investments and other non-current assets

Comments